code,parent_code,name,possibility,medical_reasoning
3A00.0,3A00,Acquired iron deficiency anaemia due to blood loss,Possible,"Key hematological features such as hemoglobin (LBXHGB), red blood cell count (LBXRBCSI), hematocrit (LBXHCT), and iron levels (LBXSIR) are available, which are essential for screening and assessing iron deficiency anemia due to blood loss."
3A00.01,3A00,Chronic posthaemorrhagic anaemia,Possible,"Key hematological features such as hemoglobin (LBXHGB), hematocrit (LBXHCT), red blood cell count (LBXRBCSI), and red cell distribution width (LBXRDW) are available, which are essential for screening chronic posthaemorrhagic anaemia. These features can help identify anemia and assess its severity, thus enabling a probabilistic model for screening."
3A00.0Z,3A00,"(Acquired iron deficiency anaemia due to blood loss, unspecified)",Possible,"The available features include key hematological parameters such as hemoglobin (LBXHGB), hematocrit (LBXHCT), red blood cell count (LBXRBCSI), and red cell distribution width (LBXRDW), which are essential for screening iron deficiency anemia. Additionally, the presence of iron levels (LBXSIR) can help assess iron status, which is crucial for diagnosing acquired iron deficiency anemia due to blood loss."
3A00.1,3A00,Acquired iron deficiency anaemia due to low intake,Possible,"Key features such as hemoglobin (LBXHGB), hematocrit (LBXHCT), red blood cell count (LBXRBCSI), and iron levels (LBXSIR) are available, which are essential for screening and assessing iron deficiency anemia."
3A00.2,3A00,Acquired iron deficiency anaemia due to decreased absorption,Possible,"Key features such as hemoglobin (LBXHGB), red blood cell count (LBXRBCSI), hematocrit (LBXHCT), and iron levels (LBXSIR) are available, which are essential for screening and assessing iron deficiency anemia."
3A00.3,3A00,Acquired iron deficiency anaemia due to increased requirement,Possible,"Key features such as hemoglobin (LBXHGB), red blood cell count (LBXRBCSI), and iron levels (LBXSIR) are available, which are essential for screening and assessing iron deficiency anemia. These features can help establish a likelihood of acquired iron deficiency anemia due to increased requirements."
3A00.Y,3A00,Other specified iron deficiency anaemia,Possible,"Key hematological parameters such as hemoglobin (LBXHGB), red blood cell count (LBXRBCSI), hematocrit (LBXHCT), mean cell volume (LBXMCVSI), and iron levels (LBXSIR) are available, which are essential for screening iron deficiency anemia."
3A00.Z,3A00,"(Iron deficiency anaemia, unspecified)",Possible,"Key hematological parameters such as hemoglobin (LBXHGB), hematocrit (LBXHCT), red blood cell count (LBXRBCSI), mean cell volume (LBXMCVSI), and red cell distribution width (LBXRDW) are available, which are essential for screening iron deficiency anemia. Additionally, iron levels (LBXSIR) can further support the assessment."
3A01.0,3A01,Hereditary vitamin B12 deficiency anaemia,Possible,"Key hematological features such as hemoglobin (LBXHGB), mean cell volume (LBXMCVSI), and red blood cell count (LBXRBCSI) are available, which can help identify macrocytic anemia typically associated with vitamin B12 deficiency. However, the absence of direct measures of vitamin B12 levels or methylmalonic acid limits definitive diagnosis but does not preclude screening for anemia."
3A01.1,3A01,Neonatal vitamin B12 deficiency anaemia,Not Possible,"Key signals for screening neonatal vitamin B12 deficiency anemia, such as serum vitamin B12 levels and methylmalonic acid (MMA) levels, are missing. The available features do not provide the necessary biochemical markers to assess vitamin B12 status or deficiency."
3A01.2,3A01,Vitamin B12 deficiency anaemia due to low intake,Possible,"Key hematological features such as hemoglobin (LBXHGB), mean cell volume (LBXMCVSI), and red blood cell count (LBXRBCSI) are available, which can help identify macrocytic anemia typically associated with vitamin B12 deficiency. However, the absence of direct measures of vitamin B12 levels or dietary intake data limits the assessment's specificity."
3A01.3,3A01,Vitamin B12 deficiency anaemia due to intrinsic factor deficiency,Possible,"Key hematological features such as hemoglobin (LBXHGB), red blood cell count (LBXRBCSI), mean cell volume (LBXMCVSI), and red cell distribution width (LBXRDW) are available, which can help identify macrocytic anemia typical of Vitamin B12 deficiency. However, intrinsic factor levels or specific vitamin B12 measurements are not included, which limits definitive diagnosis but does allow for screening based on anemia indicators."
3A01.30,3A01,Pernicious anaemia,Possible,"Key hematological features such as hemoglobin (LBXHGB), mean cell volume (LBXMCVSI), and red blood cell count (LBXRBCSI) are available, which can help identify macrocytic anemia typical of pernicious anemia. However, the absence of vitamin B12 levels or intrinsic factor measurements limits definitive diagnosis but does not preclude screening for anemia."
3A01.3Y,3A01,Other specified vitamin B12 deficiency anaemia due to intrinsic factor deficiency,Possible,"The available features include key hematological parameters such as hemoglobin (LBXHGB), red blood cell count (LBXRBCSI), mean cell volume (LBXMCVSI), and red cell distribution width (LBXRDW), which can help identify macrocytic anemia typically associated with vitamin B12 deficiency. However, intrinsic factor levels or specific vitamin B12 measurements are not available, which limits the ability to definitively diagnose the cause of the deficiency. Nonetheless, the existing features can still provide a reasonable screening framework for anemia."
3A01.4,3A01,Vitamin B12 deficiency anaemia due to intestinal disease,Possible,"Key hematological features such as hemoglobin (LBXHGB), red blood cell count (LBXRBCSI), mean cell volume (LBXMCVSI), and red cell distribution width (LBXRDW) are available, which can help identify macrocytic anemia typically associated with Vitamin B12 deficiency. However, the absence of direct measures of Vitamin B12 levels or intrinsic factor status limits the specificity of the screening."
3A01.5,3A01,Drug-induced vitamin B12 deficiency anaemia,Not Possible,"Key signals for screening drug-induced vitamin B12 deficiency anemia, such as serum vitamin B12 levels and methylmalonic acid (MMA) levels, are missing. The available features do not provide sufficient information to assess B12 status or its deficiency."
3A01.Y,3A01,Other specified megaloblastic anaemia due to vitamin B12 deficiency,Possible,"Key hematological features such as hemoglobin (LBXHGB), mean cell volume (LBXMCVSI), and red blood cell count (LBXRBCSI) are available, which can indicate megaloblastic anemia. However, the absence of vitamin B12 levels or methylmalonic acid, which are critical for confirming vitamin B12 deficiency, limits specificity. Nonetheless, the available features can still provide a reasonable screening framework for assessing likelihood."
3A01.Z,3A01,"(Megaloblastic anaemia due to vitamin B12 deficiency, unspecified)",Possible,"Key hematological features such as red blood cell count (LBXRBCSI), hemoglobin (LBXHGB), hematocrit (LBXHCT), mean cell volume (LBXMCVSI), and red cell distribution width (LBXRDW) are available, which can help identify megaloblastic anemia. However, the absence of vitamin B12 levels or methylmalonic acid, which are critical for confirming vitamin B12 deficiency, limits definitive diagnosis but does not preclude screening for anemia."
3A02.0,3A02,Hereditary folate deficiency anaemia,Not Possible,"Key signals for hereditary folate deficiency anemia, such as serum folate levels and homocysteine levels, are missing. The available features do not provide the necessary biochemical markers to assess folate status or deficiency."
3A02.1,3A02,Folate deficiency anaemia due to low intake,Possible,"Key hematological parameters such as hemoglobin (LBXHGB), red blood cell count (LBXRBCSI), mean cell volume (LBXMCVSI), and red cell distribution width (LBXRDW) are available, which can help identify macrocytic anemia indicative of folate deficiency. However, the absence of direct measures of folate levels limits the specificity of the screening."
3A02.2,3A02,Folate deficiency anaemia due to increased requirements,Possible,"Key hematological parameters such as hemoglobin (LBXHGB), red blood cell count (LBXRBCSI), mean cell volume (LBXMCVSI), and red cell distribution width (LBXRDW) are available, which can help identify macrocytic anemia indicative of folate deficiency. However, direct measurement of folate levels is not available, which limits specificity. Nonetheless, the available features can still provide a reasonable screening framework for assessing likelihood based on anemia characteristics."
3A02.3,3A02,Folate deficiency anaemia due to decreased intestinal absorption,Possible,"Key hematological parameters such as hemoglobin (LBXHGB), red blood cell count (LBXRBCSI), mean cell volume (LBXMCVSI), and red cell distribution width (LBXRDW) are available, which can indicate macrocytic anemia typically associated with folate deficiency. However, the absence of direct measures of folate levels or related metabolic markers limits specificity."
3A02.4,3A02,Drug-induced folate deficiency anaemia,Possible,"The available features include key hematological parameters such as hemoglobin (LBXHGB), red blood cell count (LBXRBCSI), mean cell volume (LBXMCVSI), and red cell distribution width (LBXRDW), which can help identify anemia. Additionally, the presence of iron levels (LBXIR) can assist in differentiating between types of anemia, including drug-induced folate deficiency anemia. However, the absence of specific folate measurements limits the ability to confirm folate deficiency directly, but the overall hematological profile can still provide a reasonable screening approach."
3A02.Y,3A02,Other specified folate deficiency anaemia,Possible,"The available features include key hematological parameters such as hemoglobin (LBXHGB), red blood cell count (LBXRBCSI), mean cell volume (LBXMCVSI), and red cell distribution width (LBXRDW), which are essential for assessing anemia. However, the absence of direct measures of folate levels (e.g., serum folate) limits the ability to definitively diagnose folate deficiency anemia. Nonetheless, the hematological features can provide a reasonable screening framework to identify individuals at risk of anemia, which may include folate deficiency."
3A02.Z,3A02,"(Folate deficiency anaemia, unspecified)",Possible,"Key hematological parameters such as hemoglobin (LBXHGB), hematocrit (LBXHCT), red blood cell count (LBXRBCSI), mean cell volume (LBXMCVSI), and red cell distribution width (LBXRDW) are available, which can help identify macrocytic anemia indicative of folate deficiency."
3A03.0,3A03,Hereditary orotic aciduria,Not Possible,"Key signals for hereditary orotic aciduria, such as orotic acid levels in urine or specific metabolic markers, are not included in the available features."
3A03.1,3A03,Protein deficiency anaemia,Possible,"Key hematological parameters such as hemoglobin (LBXHGB), red blood cell count (LBXRBCSI), hematocrit (LBXHCT), and total protein (LBXSTP) are available, which can help assess for protein deficiency anemia. These features can provide sufficient data to evaluate anemia and its potential causes, allowing for a meaningful screening approach."
3A03.2,3A03,Scorbutic anaemia,Possible,"Key hematological features such as hemoglobin (LBXHGB), hematocrit (LBXHCT), red blood cell count (LBXRBCSI), and mean cell volume (LBXMCVSI) are available, which can help identify anemia. Additionally, the presence of total protein (LBXSTP) and albumin (LBXSAL) may provide insights into nutritional status, relevant for scorbutic anemia."
3A03.3,3A03,Copper deficiency anaemia,Not Possible,"Key signals for copper deficiency anemia, such as serum copper levels and ceruloplasmin, are missing. While hematological parameters are available, they do not specifically indicate copper deficiency."
3A03.4,3A03,Acquired other vitamin B deficiency anaemia,Possible,"The available features include key hematological parameters such as hemoglobin (LBXHGB), red blood cell count (LBXRBCSI), mean cell volume (LBXMCVSI), and red cell distribution width (LBXRDW), which can help identify anemia and differentiate types, including vitamin B deficiency anemia. However, the absence of specific vitamin B levels (e.g., B12, folate) limits the ability to confirm the deficiency directly, but screening for anemia is still feasible."
3A03.40,3A03,Acquired pyridoxine deficiency anaemia,Possible,"The available features include key hematological parameters such as hemoglobin (LBXHGB), red blood cell count (LBXRBCSI), mean cell volume (LBXMCVSI), and red cell distribution width (LBXRDW), which can help identify anemia. Additionally, iron levels (LBXIR) can be assessed to rule out iron deficiency, which is crucial in differentiating types of anemia, including acquired pyridoxine deficiency anemia. However, the absence of direct measures of vitamin B6 (pyridoxine) levels limits the specificity of the screening."
3A03.41,3A03,Acquired riboflavin deficiency anaemia,Possible,"The available features include key hematological parameters such as hemoglobin (LBXHGB), red blood cell count (LBXRBCSI), mean cell volume (LBXMCVSI), and red cell distribution width (LBXRDW), which can help identify anemia. Additionally, iron levels (LBXIR) can provide insights into nutritional deficiencies, including riboflavin. However, specific riboflavin levels or dietary intake data are not available, which limits the assessment's precision. Nonetheless, the existing features can still support a probabilistic model for screening anemia related to riboflavin deficiency."
3A03.42,3A03,Acquired thiamine deficiency anaemia,Possible,"The available features include key hematological parameters such as hemoglobin (LBXHGB), red blood cell count (LBXRBCSI), mean cell volume (LBXMCVSI), and red cell distribution width (LBXRDW), which can help identify anemia. Additionally, the presence of iron levels (LBXSI) can assist in differentiating types of anemia, including thiamine deficiency. However, direct measurement of thiamine levels is not available, which is a limitation for definitive diagnosis but does not preclude screening for anemia."
3A03.4Y,3A03,Other specified acquired other vitamin B deficiency anaemia,Possible,"The available features include key hematological parameters such as hemoglobin (LBXHGB), red blood cell count (LBXRBCSI), mean cell volume (LBXMCVSI), and red cell distribution width (LBXRDW), which are essential for screening anemia. Additionally, iron levels (LBXIR) can help differentiate types of anemia, including vitamin B deficiency anemia."
3A03.5,3A03,Acquired vitamin A deficiency anaemia,Not Possible,"Key signals for screening acquired vitamin A deficiency anemia, such as serum retinol levels or dietary intake of vitamin A, are missing. The available hematological features do not provide sufficient specificity or sensitivity for this condition."
3A03.6,3A03,Acquired vitamin E deficiency anaemia,Not Possible,"Key signals for acquired vitamin E deficiency anemia, such as vitamin E levels or specific dietary intake data, are missing. The available features do not provide the necessary biochemical markers to assess vitamin E status or deficiency."
3A03.Y,3A03,Other and unspecified nutritional or metabolic anaemia,Possible,"Key hematological parameters such as hemoglobin (LBXHGB), hematocrit (LBXHCT), red blood cell count (LBXRBCSI), and red cell distribution width (LBXRDW) are available, which are essential for screening various types of anemia, including nutritional or metabolic anemia. Additionally, iron levels (LBXIR) can help assess iron deficiency anemia, a common cause of nutritional anemia."
3A10.0,3A10,Haemolytic anaemias due to hexose monophosphate shunt or glutathione metabolism anomalies,Possible,"The available features include key hematological parameters such as hemoglobin (LBXHGB), hematocrit (LBXHCT), red blood cell count (LBXRBCSI), and lactate dehydrogenase (LBXSLDSI), which can indicate hemolysis. Additionally, total bilirubin (LBXSTB) can help assess jaundice associated with hemolytic anemia. These features can be used to screen for hemolytic anemias due to metabolic anomalies."
3A10.00,3A10,Haemolytic anaemia due to glucose-6-phosphate dehydrogenase deficiency,Possible,"Key hematological features such as hemoglobin (LBXHGB), hematocrit (LBXHCT), red blood cell count (LBXRBCSI), and lactate dehydrogenase (LBXSLDSI) can indicate hemolysis, while total bilirubin (LBXSTB) can suggest increased breakdown of red blood cells, which are relevant for screening G6PD deficiency. However, the absence of G6PD enzyme activity testing limits definitive diagnosis but does not preclude screening based on hematological parameters."
3A10.0Y,3A10,Other specified haemolytic anaemias due to hexose monophosphate shunt or glutathione metabolism anomalies,Possible,"The available features include key hematological parameters such as hemoglobin (LBXHGB), hematocrit (LBXHCT), red blood cell count (LBXRBCSI), and lactate dehydrogenase (LBXSLDSI), which are critical for assessing hemolytic anemia. Additionally, total bilirubin (LBXSTB) can indicate hemolysis. These features can be used to build a probabilistic model for screening hemolytic anemias."
3A10.0Z,3A10,"(Haemolytic anaemias due to hexose monophosphate shunt or glutathione metabolism anomalies, unspecified)",Possible,"Key hematological features such as hemoglobin (LBXHGB), hematocrit (LBXHCT), red blood cell count (LBXRBCSI), and lactate dehydrogenase (LBXSLDSI) are available, which can indicate hemolysis and anemia. However, the absence of specific markers for hexose monophosphate shunt or glutathione metabolism anomalies limits the precision of screening. Nonetheless, the available features can still provide a reasonable basis for assessing likelihood."
3A10.1,3A10,Haemolytic anaemia due to adenosine deaminase excess,Possible,"Key hematological features such as red blood cell count (LBXRBCSI), hemoglobin (LBXHGB), hematocrit (LBXHCT), lactate dehydrogenase (LBXSLDSI), and total bilirubin (LBXSTB) are available, which can help identify hemolytic anemia. However, the absence of specific markers for adenosine deaminase activity limits the precision of the screening. Nonetheless, the available features can still provide a reasonable basis for assessing the likelihood of hemolytic anemia."
3A10.2,3A10,Hereditary elliptocytosis,Not Possible,"Key features such as specific genetic markers or tests for membrane stability (e.g., osmotic fragility test) are essential for screening hereditary elliptocytosis, which are not available in the listed NHANES features."
3A10.3,3A10,Familial pseudohyperkalaemia,Not Possible,"Familial pseudohyperkalaemia is characterized by elevated serum potassium levels without true hyperkalemia, often requiring genetic testing or specific potassium handling assessments. The available features do not include genetic markers or specific tests for potassium handling, making screening not feasible."
3A10.Y,3A10,Other specified hereditary haemolytic anaemia,Possible,"The available features include key hematological parameters such as hemoglobin (LBXHGB), hematocrit (LBXHCT), red blood cell count (LBXRBCSI), and lactate dehydrogenase (LBXSLDSI), which can indicate hemolysis. Additionally, total bilirubin (LBXSTB) can help assess for hemolytic anemia. These features can be used to screen for hereditary hemolytic anemia by evaluating anemia and hemolysis indicators."
3A10.Z,3A10,"(Hereditary haemolytic anaemia, unspecified)",Possible,"Key hematological features such as hemoglobin (LBXHGB), hematocrit (LBXHCT), red blood cell count (LBXRBCSI), and red cell distribution width (LBXRDW) are available, which can help identify anemia and suggest hemolytic processes. However, the absence of specific markers for hereditary conditions (e.g., genetic testing or specific enzyme assays) limits definitive diagnosis but does not preclude screening for anemia."
3A20.0,3A20,"(Autoimmune haemolytic anaemia, warm type)",Possible,"Key features such as hemoglobin (LBXHGB), red blood cell count (LBXRBCSI), and lactate dehydrogenase (LBXSLDSI) are available, which can indicate hemolysis and anemia. Additionally, total bilirubin (LBXSTB) can help assess for hemolytic processes, making screening for autoimmune hemolytic anemia feasible."
3A20.1,3A20,"(Autoimmune haemolytic anaemia, cold type)",Possible,"Key features such as hemoglobin (LBXHGB), red blood cell count (LBXRBCSI), and lactate dehydrogenase (LBXSLDSI) can indicate hemolysis, while total bilirubin (LBXSTB) can suggest increased breakdown of red blood cells, which are essential for screening autoimmune hemolytic anemia."
3A20.2,3A20,"(Autoimmune haemolytic anaemia, mixed type, cold and warm)",Possible,"Key hematological features such as red blood cell count (LBXRBCSI), hemoglobin (LBXHGB), hematocrit (LBXHCT), and lactate dehydrogenase (LBXSLDSI) are available, which can indicate hemolysis. Additionally, total bilirubin (LBXSTB) can help assess for hemolytic anemia. These features allow for a reasonable screening approach for autoimmune hemolytic anemia."
3A20.3,3A20,Paroxysmal cold haemoglobinuria,Not Possible,"Key signals for paroxysmal cold hemoglobinuria, such as direct Coombs test results, specific hemolysis markers (e.g., haptoglobin levels), and cold agglutinins, are missing. The available features do not provide sufficient information to screen or assess likelihood effectively."
3A20.4,3A20,Alloimmune haemolytic anaemia,Possible,"Key hematological parameters such as hemoglobin (LBXHGB), red blood cell count (LBXRBCSI), and lactate dehydrogenase (LBXSLDSI) can indicate hemolysis, while total bilirubin (LBXSTB) can suggest increased breakdown of red blood cells, which are relevant for screening alloimmune hemolytic anemia."
3A20.5,3A20,Evans syndrome,Possible,"The available features include key hematological parameters such as white blood cell count (LBXWBCSI), lymphocyte percent (LBXLYPCT), red blood cell count (LBXRBCSI), hemoglobin (LBXHGB), and platelet count (LBXPLTSI), which can help identify the cytopenias and hemolysis associated with Evans syndrome. However, the absence of specific markers for autoimmune hemolytic anemia or direct Coombs test results limits the specificity of the assessment. Nonetheless, the existing features can still provide a reasonable basis for screening."
3A20.Y,3A20,"(Other specified acquired haemolytic anaemia, immune)",Possible,"Key hematological features such as hemoglobin (LBXHGB), hematocrit (LBXHCT), red blood cell count (LBXRBCSI), and lactate dehydrogenase (LBXSLDSI) are available, which can indicate hemolysis. Additionally, total bilirubin (LBXSTB) can help assess for hemolytic anemia. However, the absence of direct markers for immune-mediated hemolysis (e.g., direct Coombs test) limits specificity. Nonetheless, the available features can still support a probabilistic model for screening."
3A21.0,3A21,Paroxysmal nocturnal haemoglobinuria,Not Possible,"Key diagnostic features for Paroxysmal nocturnal hemoglobinuria (PNH) such as flow cytometry for CD55 and CD59 expression on red blood cells, and specific tests for hemolysis (e.g., haptoglobin levels, reticulocyte count) are not available. The listed features do not provide the necessary signals to effectively screen or assess the likelihood of PNH."
3A21.1,3A21,Microangiopathic haemolytic anaemia,Possible,"Key hematological features such as hemoglobin (LBXHGB), hematocrit (LBXHCT), red blood cell count (LBXRBCSI), lactate dehydrogenase (LBXSLDSI), and total bilirubin (LBXSTB) are available, which can indicate hemolysis and anemia. These features can help in screening for microangiopathic hemolytic anemia by assessing for signs of hemolysis and anemia, thus allowing for a meaningful likelihood assessment."
3A21.2,3A21,Haemolytic uraemic syndrome,Possible,"Key features such as hemoglobin (LBXHGB), hematocrit (LBXHCT), lactate dehydrogenase (LBXSLDSI), and platelet count (LBXPLTSI) are available, which can indicate hemolysis and thrombocytopenia, both critical in assessing hemolytic uremic syndrome. However, the absence of specific renal function tests (e.g., creatinine clearance) limits the assessment of renal involvement, but overall screening remains feasible."
3A21.Y,3A21,"(Other specified acquired haemolytic anaemia, non-immune)",Possible,"Key hematological parameters such as red blood cell count (LBXRBCSI), hemoglobin (LBXHGB), hematocrit (LBXHCT), lactate dehydrogenase (LBXSLDSI), and total bilirubin (LBXSTB) are available, which can indicate hemolysis and support screening for acquired hemolytic anemia."
3A50.0,3A50,Alpha thalassaemia,Possible,"Key hematological features such as hemoglobin (LBXHGB), red blood cell count (LBXRBCSI), mean cell volume (LBXMCVSI), and red cell distribution width (LBXRDW) are available, which can help identify microcytic anemia and other abnormalities associated with alpha thalassemia."
3A50.00,3A50,Mild alpha thalassaemia diseases,Possible,"Key hematological features such as red blood cell count (LBXRBCSI), hemoglobin (LBXHGB), hematocrit (LBXHCT), mean cell volume (LBXMCVSI), and red cell distribution width (LBXRDW) are available, which can help identify microcytic anemia and other abnormalities associated with mild alpha thalassemia."
3A50.01,3A50,Thalassaemic alpha-chain variants,Possible,"Key hematological features such as hemoglobin (LBXHGB), red blood cell count (LBXRBCSI), mean cell volume (LBXMCVSI), and red cell distribution width (LBXRDW) are available, which can help identify thalassaemia through microcytic anemia and other red cell indices."
3A50.02,3A50,Haemoglobin H disease (- alpha / -- included),Possible,"Key hematological features such as hemoglobin (LBXHGB), hematocrit (LBXHCT), mean cell volume (LBXMCVSI), and red blood cell count (LBXRBCSI) are available, which can help identify microcytic anemia and abnormal hemoglobin levels indicative of Haemoglobin H disease."
3A50.03,3A50,Homozygous or compound heterozygous alpha0 thalassaemia,Possible,"The available features include key hematological parameters such as hemoglobin (LBXHGB), red blood cell count (LBXRBCSI), mean cell volume (LBXMCVSI), and red cell distribution width (LBXRDW), which are essential for screening thalassemia. These features can help identify microcytic anemia and other hematological abnormalities associated with alpha thalassemia. However, genetic testing or specific hemoglobin electrophoresis results are not available, which limits definitive diagnosis but does not preclude screening."
3A50.0Y,3A50,Other specified alpha thalassaemia,Possible,"Key hematological features such as hemoglobin (LBXHGB), red blood cell count (LBXRBCSI), mean cell volume (LBXMCVSI), and red cell distribution width (LBXRDW) are available, which can help identify microcytic anemia typical of alpha thalassemia. However, genetic testing or specific hemoglobin electrophoresis results are not available, which limits definitive diagnosis but does allow for screening based on hematological parameters."
3A50.0Z,3A50,"(Alpha thalassaemia, unspecified)",Possible,"Key hematological features such as red blood cell count (LBXRBCSI), hemoglobin (LBXHGB), hematocrit (LBXHCT), mean cell volume (LBXMCVSI), and red cell distribution width (LBXRDW) are available, which can help identify microcytic anemia typical of alpha thalassemia."
3A50.1,3A50,Alpha thalassaemia related syndromes,Possible,"Key hematological features such as hemoglobin (LBXHGB), red blood cell count (LBXRBCSI), mean cell volume (LBXMCVSI), and red cell distribution width (LBXRDW) are available, which can help identify microcytic anemia typical of alpha thalassemia. However, genetic testing or specific hemoglobin electrophoresis results are not available, which limits definitive diagnosis but does allow for screening based on hematological parameters."
3A50.2,3A50,Beta thalassaemia,Possible,"Key hematological features such as hemoglobin (LBXHGB), red blood cell count (LBXRBCSI), mean cell volume (LBXMCVSI), and red cell distribution width (LBXRDW) are available, which can help identify microcytic anemia characteristic of beta thalassemia. However, genetic testing or specific hemoglobin electrophoresis results are not available, which limits definitive diagnosis but does allow for screening based on hematological parameters."
3A50.3,3A50,"(Delta, delta-beta or gamma-delta-beta thalassaemia)",Possible,"Key hematological features such as hemoglobin (LBXHGB), red blood cell count (LBXRBCSI), mean cell volume (LBXMCVSI), and red cell distribution width (LBXRDW) are available, which can help identify thalassemia traits. These features can be used to assess the likelihood of delta-beta or gamma-delta-beta thalassemia through a combination of microcytic anemia and abnormal red cell indices."
3A50.4,3A50,Hereditary persistence of fetal haemoglobin,Not Possible,"Key signals for screening hereditary persistence of fetal hemoglobin, such as specific hemoglobin electrophoresis results or genetic testing for HBF persistence, are not available in the listed features."
3A50.Y,3A50,Other specified thalassaemias,Possible,"Key hematological features such as hemoglobin (LBXHGB), red blood cell count (LBXRBCSI), mean cell volume (LBXMCVSI), and red cell distribution width (LBXRDW) are available, which can help identify thalassemia traits. These features allow for the assessment of microcytic anemia and other hematological abnormalities associated with thalassemias."
3A50.Z,3A50,"(Thalassaemias, unspecified)",Possible,"The available features include key hematological parameters such as hemoglobin (LBXHGB), hematocrit (LBXHCT), mean cell volume (LBXMCVSI), and red blood cell count (LBXRBCSI), which are essential for screening thalassemias. These features can help identify microcytic anemia and other abnormalities associated with thalassemias, allowing for a probabilistic model to assess disease likelihood."
3A51.0,3A51,Sickle cell trait,Not Possible,"Sickle cell trait screening typically requires hemoglobin electrophoresis or genetic testing to identify the presence of the HbS allele. The available features do not include any specific tests for hemoglobin variants or genetic markers, which are essential for accurate screening."
3A51.1,3A51,Sickle cell disease without crisis,Possible,"Key hematological features such as hemoglobin (LBXHGB), red blood cell count (LBXRBCSI), and red cell distribution width (LBXRDW) are available, which can help identify sickle cell disease through abnormal values indicative of hemolysis and anemia."
3A51.2,3A51,Sickle cell disease with crisis,Possible,"Key hematological features such as hemoglobin (LBXHGB), red blood cell count (LBXRBCSI), and lactate dehydrogenase (LBXSLDSI) can indicate sickle cell disease and its complications. Additionally, the presence of uric acid (LBXSUA) can help assess for vaso-occlusive crises. These features allow for a probabilistic model to screen for the disease effectively."
3A51.3,3A51,Compound heterozygous sickling disorders without crisis,Possible,"The available features include key hematological parameters such as hemoglobin (LBXHGB), red blood cell count (LBXRBCSI), hematocrit (LBXHCT), and red cell distribution width (LBXRDW), which are essential for screening sickling disorders. These features can help identify anemia and abnormal red blood cell morphology indicative of sickle cell disease. However, genetic testing or specific hemoglobin electrophoresis results are not available, which limits definitive diagnosis but does not preclude screening."
3A51.4,3A51,Compound heterozygous sickling disorders with crisis,Not Possible,"Key signals for screening compound heterozygous sickling disorders, such as hemoglobin electrophoresis or genetic testing for sickle cell mutations, are missing. While hematological parameters like hemoglobin and red blood cell count are available, they are insufficient for definitive screening or triage of this specific disorder."
3A51.5,3A51,Haemoglobin C disease,Possible,"Key hematological features such as hemoglobin (LBXHGB), red blood cell count (LBXRBCSI), mean cell volume (LBXMCVSI), and red cell distribution width (LBXRDW) are available, which can help identify abnormalities associated with Hemoglobin C disease."
3A51.6,3A51,Haemoglobin D disease,Possible,"Key hematological features such as hemoglobin (LBXHGB), red blood cell count (LBXRBCSI), and mean cell volume (LBXMCVSI) are available, which can help identify abnormalities associated with Haemoglobin D disease. These features can be used to assess the likelihood of the disease through screening for characteristic hematological changes."
3A51.7,3A51,High affinity haemoglobin,Possible,"The available features include hemoglobin levels (LBXHGB), hematocrit (LBXHCT), red blood cell count (LBXRBCSI), and mean cell volume (LBXMCVSI), which are critical for assessing high affinity hemoglobin conditions. These features can help identify abnormalities in oxygen transport and red blood cell characteristics, allowing for effective screening."
3A51.8,3A51,Low affinity haemoglobin,Possible,"Key hematological features such as hemoglobin (LBXHGB), red blood cell count (LBXRBCSI), mean cell volume (LBXMCVSI), and red cell distribution width (LBXRDW) are available, which can help assess low affinity hemoglobin conditions."
3A51.9,3A51,Haemoglobin O disease,Possible,"Key hematological features such as hemoglobin (LBXHGB), red blood cell count (LBXRBCSI), and mean cell volume (LBXMCVSI) are available, which can help identify abnormalities associated with Haemoglobin O disease. These features can be used to screen for hemoglobinopathies and assess the likelihood of the disease."
3A51.A,3A51,Haemoglobin E disease,Possible,"Key hematological features such as hemoglobin (LBXHGB), red blood cell count (LBXRBCSI), mean cell volume (LBXMCVSI), and red cell distribution width (LBXRDW) are available, which can help identify abnormalities associated with Haemoglobin E disease."
3A51.B,3A51,Haemoglobin C/beta thalassaemia compound heterozygosity,Possible,"The available features include key hematological parameters such as hemoglobin (LBXHGB), red blood cell count (LBXRBCSI), mean cell volume (LBXMCVSI), and red cell distribution width (LBXRDW), which can help identify abnormalities associated with hemoglobin C/beta thalassemia. However, genetic testing or specific hemoglobin electrophoresis results are not available, which limits definitive diagnosis but does allow for screening based on hematological profiles."
3A51.Y,3A51,Other specified sickle cell disorders or other haemoglobinopathies,Possible,"The available features include key hematological parameters such as hemoglobin (LBXHGB), red blood cell count (LBXRBCSI), hematocrit (LBXHCT), and red cell distribution width (LBXRDW), which are essential for screening sickle cell disorders and other hemoglobinopathies. These features can help identify anemia and abnormal red blood cell morphology indicative of such conditions."
3A51.Z,3A51,"(Sickle cell disorders or other haemoglobinopathies, unspecified)",Possible,"Key hematological features such as hemoglobin (LBXHGB), red blood cell count (LBXRBCSI), hematocrit (LBXHCT), and red cell distribution width (LBXRDW) are available, which can help identify abnormalities associated with sickle cell disorders and other hemoglobinopathies."
3A60.0,3A60,Congenital non-inherited pure red cell aplasia,Possible,"Key hematological features such as red blood cell count (LBXRBCSI), hemoglobin (LBXHGB), hematocrit (LBXHCT), and red cell distribution width (LBXRDW) are available, which can help identify anemia and red cell aplasia. However, the absence of specific genetic markers or additional tests for congenital causes limits the precision of the assessment."
3A60.1,3A60,Hereditary pure red cell aplasia,Possible,"The available features include key hematological parameters such as red blood cell count (LBXRBCSI), hemoglobin (LBXHGB), hematocrit (LBXHCT), and red cell distribution width (LBXRDW), which are essential for screening and assessing red cell aplasia. These features can help identify abnormalities in red blood cell production and support a probabilistic model for hereditary pure red cell aplasia."
3A60.Z,3A60,"(Congenital pure red cell aplasia, unspecified)",Possible,"The available features include key hematological parameters such as red blood cell count (LBXRBCSI), hemoglobin (LBXHGB), hematocrit (LBXHCT), and red cell distribution width (LBXRDW), which are essential for screening congenital pure red cell aplasia. These features can help identify anemia and abnormal red cell production, which are indicative of the condition."
3A61.0,3A61,Acute acquired pure red cell aplasia,Possible,"The available features include key hematological parameters such as red blood cell count (LBXRBCSI), hemoglobin (LBXHGB), hematocrit (LBXHCT), and red cell distribution width (LBXRDW), which are essential for screening acute acquired pure red cell aplasia. These features can help identify significant anemia and changes in red cell production, which are indicative of the disease."
3A61.1,3A61,Chronic acquired pure red cell aplasia,Possible,"Key hematological features such as red blood cell count (LBXRBCSI), hemoglobin (LBXHGB), hematocrit (LBXHCT), and red cell distribution width (LBXRDW) are available, which can help identify anemia and suggest red cell aplasia. However, the absence of specific markers for underlying causes (e.g., autoimmune markers, viral serologies) limits the depth of assessment."
3A61.Y,3A61,Other specified acquired pure red cell aplasia,Possible,"The available features include key hematological parameters such as red blood cell count (LBXRBCSI), hemoglobin (LBXHGB), hematocrit (LBXHCT), and red cell distribution width (LBXRDW), which are essential for assessing anemia and can help identify pure red cell aplasia. Additionally, white blood cell count (LBXWBCSI) and lymphocyte counts (LBXLYPCT) can provide further context. However, the absence of specific markers or tests for underlying causes of acquired pure red cell aplasia (e.g., autoimmune markers, bone marrow biopsy results) limits the depth of assessment. Nonetheless, the existing features allow for a preliminary screening approach."
3A61.Z,3A61,"(Acquired pure red cell aplasia, unspecified)",Possible,"The available features include key hematological parameters such as red blood cell count (LBXRBCSI), hemoglobin (LBXHGB), hematocrit (LBXHCT), and red cell distribution width (LBXRDW), which are essential for screening and assessing red cell aplasia. These features can help identify anemia and changes in red cell production, which are indicative of acquired pure red cell aplasia."
3A70.0,3A70,Congenital aplastic anaemia,Possible,"Key hematological features such as white blood cell count (LBXWBCSI), red blood cell count (LBXRBCSI), hemoglobin (LBXHGB), hematocrit (LBXHCT), and platelet count (LBXPLTSI) are available, which can help identify cytopenias characteristic of congenital aplastic anemia."
3A70.1,3A70,Acquired aplastic anaemias,Possible,"Key hematological parameters such as white blood cell count (LBXWBCSI), red blood cell count (LBXRBCSI), hemoglobin (LBXHGB), hematocrit (LBXHCT), and platelet count (LBXPLTSI) are available, which can help identify cytopenias characteristic of acquired aplastic anemia."
3A70.10,3A70,Drug-induced aplastic anaemia,Possible,"The available features include key hematological parameters such as white blood cell count (LBXWBCSI), red blood cell count (LBXRBCSI), hemoglobin (LBXHGB), hematocrit (LBXHCT), and platelet count (LBXPLTSI), which are essential for screening aplastic anemia. However, the absence of specific drug exposure history or genetic markers limits the ability to definitively assess drug-induced causes. Nonetheless, the hematological features can still provide a basis for screening."
3A70.11,3A70,Aplastic anaemia due to other external agents,Possible,"The available features include key hematological parameters such as white blood cell count (LBXWBCSI), red blood cell count (LBXRBCSI), hemoglobin (LBXHGB), hematocrit (LBXHCT), and platelet count (LBXPLTSI), which are essential for screening aplastic anemia. These features can help identify cytopenias characteristic of the disease, thus enabling a probabilistic model for screening."
3A70.12,3A70,Idiopathic aplastic anaemia,Possible,"Key hematological features such as white blood cell count (LBXWBCSI), red blood cell count (LBXRBCSI), hemoglobin (LBXHGB), hematocrit (LBXHCT), and platelet count (LBXPLTSI) are available, which can help identify cytopenias characteristic of idiopathic aplastic anemia. However, the absence of bone marrow analysis or specific genetic markers limits definitive diagnosis but does not preclude screening for likelihood assessment."
3A70.1Y,3A70,Other specified acquired aplastic anaemias,Possible,"The available features include key hematological parameters such as white blood cell count (LBXWBCSI), red blood cell count (LBXRBCSI), hemoglobin (LBXHGB), hematocrit (LBXHCT), and platelet count (LBXPLTSI), which are essential for screening aplastic anemia. These features can help identify cytopenias characteristic of the disease, thus enabling a probabilistic model for screening."
3A70.1Z,3A70,"(Acquired aplastic anaemias, unspecified)",Possible,"The available features include key hematological parameters such as white blood cell count (LBXWBCSI), red blood cell count (LBXRBCSI), hemoglobin (LBXHGB), hematocrit (LBXHCT), and platelet count (LBXPLTSI), which are essential for screening aplastic anemia. These features can help identify cytopenias characteristic of the disease, thus enabling a probabilistic model for screening."
3A70.Z,3A70,"(Aplastic anaemia, unspecified)",Possible,"Aplastic anemia can be screened using features such as white blood cell count (LBXWBCSI), red blood cell count (LBXRBCSI), hemoglobin (LBXHGB), hematocrit (LBXHCT), and platelet count (LBXPLTSI). These hematological parameters are critical for assessing bone marrow function and identifying cytopenias characteristic of aplastic anemia."
3A71.0,3A71,Anaemia in neoplastic disease,Possible,"Key hematological parameters such as hemoglobin (LBXHGB), red blood cell count (LBXRBCSI), hematocrit (LBXHCT), and red cell distribution width (LBXRDW) are available, which are essential for screening anemia. Additionally, the presence of white blood cell count (LBXWBCSI) and other blood cell types can help assess underlying neoplastic processes."
3A71.1,3A71,Anaemia in chronic infectious diseases,Possible,"The available features include key hematological parameters such as hemoglobin (LBXHGB), red blood cell count (LBXRBCSI), hematocrit (LBXHCT), and white blood cell count (LBXWBCSI), which are essential for screening anemia. Additionally, the presence of inflammatory markers like white blood cell count can help assess the likelihood of anemia in chronic infectious diseases."
3A71.2,3A71,Anaemia in chronic kidney disease,Possible,"Key features such as hemoglobin (LBXHGB), hematocrit (LBXHCT), red blood cell count (LBXRBCSI), and creatinine (LBXSCR) are available, which are essential for screening anemia and assessing kidney function, thus enabling a probabilistic model for anemia in chronic kidney disease."
3A71.Y,3A71,Anaemia due to other specified chronic disease,Possible,"The available features include key hematological parameters such as hemoglobin (LBXHGB), hematocrit (LBXHCT), red blood cell count (LBXRBCSI), and red cell distribution width (LBXRDW), which are essential for screening anemia. Additionally, the presence of white blood cell count (LBXWBCSI) and other blood cell types can help assess underlying chronic diseases contributing to anemia."
3A71.Z,3A71,"(Anaemia due to chronic disease, unspecified)",Possible,"Key hematological parameters such as hemoglobin (LBXHGB), red blood cell count (LBXRBCSI), hematocrit (LBXHCT), and red cell distribution width (LBXRDW) are available, which are essential for screening anemia. Additionally, the presence of albumin (LBXSAL) and iron (LBXIR) can help assess chronic disease states contributing to anemia."
3A72.0,3A72,Congenital sideroblastic anaemias,Possible,"The available features include key hematological parameters such as hemoglobin (LBXHGB), red blood cell count (LBXRBCSI), mean cell volume (LBXMCVSI), and red cell distribution width (LBXRDW), which can help identify microcytic anemia and other abnormalities associated with congenital sideroblastic anemias. However, the absence of specific iron studies (e.g., serum ferritin, transferrin saturation) limits the ability to fully characterize iron metabolism, which is crucial for definitive screening. Nonetheless, the existing features can still provide a reasonable basis for initial screening and likelihood assessment."
3A72.00,3A72,Hereditary sideroblastic anaemias,Possible,"Key hematological features such as hemoglobin (LBXHGB), red blood cell count (LBXRBCSI), mean cell volume (LBXMCVSI), and red cell distribution width (LBXRDW) are available, which can help identify microcytic anemia and abnormal red cell morphology indicative of sideroblastic anemia. However, genetic testing or specific iron studies (like serum ferritin) are not listed, which could limit definitive diagnosis but do not preclude screening."
3A72.01,3A72,Hereditary syndromic sideroblastic anaemia,Not Possible,"Key signals for hereditary syndromic sideroblastic anemia, such as specific iron studies (e.g., serum ferritin, transferrin saturation), genetic testing for mutations, and bone marrow examination for ringed sideroblasts, are missing. The available features do not provide sufficient information to screen or assess likelihood effectively."
3A72.0Y,3A72,Other specified congenital sideroblastic anaemias,Possible,"The available features include key hematological parameters such as hemoglobin (LBXHGB), red blood cell count (LBXRBCSI), mean cell volume (LBXMCVSI), and red cell distribution width (LBXRDW), which are essential for screening and assessing anemia, including congenital sideroblastic anemia. However, the absence of specific iron studies (e.g., serum ferritin, transferrin saturation) limits the ability to fully characterize the iron metabolism abnormalities typically associated with sideroblastic anemia. Despite this, the existing features can still provide a reasonable basis for screening."
3A72.0Z,3A72,"(Congenital sideroblastic anaemias, unspecified)",Possible,"The available features include key hematological parameters such as red blood cell count (LBXRBCSI), hemoglobin (LBXHGB), hematocrit (LBXHCT), mean cell volume (LBXMCVSI), and red cell distribution width (LBXRDW), which are essential for screening and assessing anemia, including congenital sideroblastic anemias. However, the absence of specific iron studies (e.g., serum ferritin, transferrin saturation) limits the ability to fully characterize the iron metabolism abnormalities typically associated with sideroblastic anemia. Despite this, the existing features can still provide a reasonable basis for screening."
3A72.1,3A72,Acquired sideroblastic anaemias,Possible,"Key hematological parameters such as red blood cell count (LBXRBCSI), hemoglobin (LBXHGB), hematocrit (LBXHCT), mean cell volume (LBXMCVSI), and red cell distribution width (LBXRDW) are available, which can help identify abnormalities consistent with acquired sideroblastic anemias. However, iron studies (e.g., serum iron, ferritin) are not listed, which limits the ability to fully assess iron metabolism, a critical aspect of this condition. Nonetheless, the available features can still provide a reasonable basis for screening."
3A72.Z,3A72,"(Sideroblastic anaemia, unspecified)",Possible,"Key hematological parameters such as hemoglobin (LBXHGB), red blood cell count (LBXRBCSI), mean cell volume (LBXMCVSI), and red cell distribution width (LBXRDW) are available, which can help identify microcytic anemia and assess iron metabolism, both relevant for sideroblastic anemia screening. However, iron studies (e.g., serum iron, ferritin) are not listed, which limits the ability to fully characterize the anemia type."
3A80.0,3A80,Primary inherited erythrocytosis,Possible,"The available features include key hematological parameters such as red blood cell count (LBXRBCSI), hemoglobin (LBXHGB), and hematocrit (LBXHCT), which are essential for screening erythrocytosis. These features can help identify elevated red cell mass indicative of primary inherited erythrocytosis."
3A80.Y,3A80,Other specified congenital polycythaemia,Possible,"The available features include key hematological parameters such as red blood cell count (LBXRBCSI), hemoglobin (LBXHGB), and hematocrit (LBXHCT), which are essential for assessing polycythemia. These features can help identify elevated red cell mass indicative of congenital polycythemia, allowing for a meaningful screening approach."
3A80.Z,3A80,"(Congenital polycythaemia, unspecified)",Possible,"The available features include key hematological parameters such as red blood cell count (LBXRBCSI), hemoglobin (LBXHGB), and hematocrit (LBXHCT), which are essential for screening polycythemia. These features can help identify elevated red cell mass indicative of congenital polycythemia."
3A81.0,3A81,"(Polycythaemia due to hypoxia, including high altitude)",Possible,"Key hematological features such as red blood cell count (LBXRBCSI), hemoglobin (LBXHGB), and hematocrit (LBXHCT) are available, which are essential for screening polycythemia. These features can help identify elevated red cell mass indicative of polycythemia due to hypoxia."
3A81.1,3A81,Polycythaemia due to over-transfusion or blood doping,Possible,"Key hematological parameters such as red blood cell count (LBXRBCSI), hemoglobin (LBXHGB), and hematocrit (LBXHCT) are available, which are essential for screening polycythaemia. These features can help identify elevated red cell mass indicative of polycythaemia due to over-transfusion or blood doping."
3A81.2,3A81,Relative polycythaemia,Possible,"Relative polycythemia can be assessed using available features such as red blood cell count (LBXRBCSI), hemoglobin (LBXHGB), and hematocrit (LBXHCT), which are critical for identifying elevated red cell mass. Additionally, age (RIDAGEYR) and gender (RIAGENDR) can help stratify risk."
3A81.Y,3A81,Other specified acquired polycythaemia,Possible,"The available features include key hematological parameters such as red blood cell count (LBXRBCSI), hemoglobin (LBXHGB), and hematocrit (LBXHCT), which are essential for assessing polycythemia. These features can help identify elevated red cell mass indicative of acquired polycythemia."
3A81.Z,3A81,"(Acquired polycythaemia, unspecified)",Possible,"The available features include key hematological parameters such as red blood cell count (LBXRBCSI), hemoglobin (LBXHGB), and hematocrit (LBXHCT), which are essential for screening polycythemia. These features can help identify elevated red cell mass indicative of acquired polycythemia."
3A8Z,3A8Z,"(Polycythaemia, unspecified)",Possible,"Key hematological parameters such as red blood cell count (LBXRBCSI), hemoglobin (LBXHGB), and hematocrit (LBXHCT) are available, which are essential for screening polycythaemia. These features can help identify elevated red cell mass indicative of the condition."
3A90,3A90,Anaemia due to acute disease,Possible,"Key hematological parameters such as hemoglobin (LBXHGB), hematocrit (LBXHCT), red blood cell count (LBXRBCSI), and white blood cell count (LBXWBCSI) are available, which are essential for screening anemia due to acute disease. These features can help assess the presence of anemia and its potential causes, thus enabling a meaningful screening process."
3A91,3A91,Congenital methaemoglobinaemia,Not Possible,"Key signals for congenital methaemoglobinaemia, such as methemoglobin levels or specific genetic markers, are not included in the available features. The listed hematological parameters do not provide sufficient information to screen for this condition."
3A92,3A92,Hereditary methaemoglobinaemia,Not Possible,"Key signals for hereditary methaemoglobinaemia, such as methemoglobin levels or specific genetic markers, are not included in the available features."
3A93,3A93,Acquired methaemoglobinaemia,Not Possible,"Key signals for acquired methaemoglobinaemia, such as methemoglobin levels or specific blood gas analyses, are not included in the available features."
3A94,3A94,Acute posthaemorrhagic anaemia,Possible,"Key hematological parameters such as hemoglobin (LBXHGB), hematocrit (LBXHCT), red blood cell count (LBXRBCSI), and red cell distribution width (LBXRDW) are available, which are essential for screening acute posthaemorrhagic anaemia. These features can help identify anemia and assess its severity, thus enabling a probabilistic model for screening."
3A9Y,3A9Y,Other specified anaemias or erythrocyte disorders,Possible,"The available features include key hematological parameters such as hemoglobin (LBXHGB), red blood cell count (LBXRBCSI), hematocrit (LBXHCT), mean cell volume (LBXMCVSI), and red cell distribution width (LBXRDW), which are essential for screening various anemias. These features can help identify abnormalities in erythrocyte disorders, thus enabling a probabilistic model for assessing the likelihood of other specified anemias."
3A9Z,3A9Z,"(Anaemias or other erythrocyte disorders, unspecified)",Possible,"The available features include key hematological parameters such as hemoglobin (LBXHGB), hematocrit (LBXHCT), red blood cell count (LBXRBCSI), and red cell distribution width (LBXRDW), which are essential for screening various anemias. These features can help assess erythrocyte disorders and provide a basis for further evaluation."
3B10.0,3B10,Haemophilia A,Not Possible,"Key signals for screening Haemophilia A, such as factor VIII activity levels or specific genetic testing for mutations in the F8 gene, are not included in the available features."
3B10.1,3B10,Hereditary factor VIII deficiency with anti-factor VIII inhibitor,Not Possible,"Key signals for screening hereditary factor VIII deficiency, such as specific factor VIII activity assays and inhibitor testing, are not available in the listed features."
3B10.Y,3B10,Other specified hereditary factor VIII deficiency,Not Possible,"Key signals for screening hereditary factor VIII deficiency, such as specific factor VIII activity assays or genetic testing for mutations in the F8 gene, are not available in the listed features."
3B10.Z,3B10,"(Hereditary factor VIII deficiency, unspecified)",Not Possible,"Key signals for screening hereditary factor VIII deficiency, such as specific factor VIII activity assays or genetic testing for mutations in the F8 gene, are not available in the listed features."
3B11.0,3B11,Haemophilia B,Not Possible,"Key signals for screening Haemophilia B, such as specific factor IX activity levels or genetic testing for mutations in the F9 gene, are not available in the listed features. The available hematological parameters do not provide sufficient specificity or sensitivity for screening this condition."
3B11.Y,3B11,Other specified hereditary factor IX deficiency,Not Possible,"Key signals for screening hereditary factor IX deficiency, such as specific coagulation factor assays (e.g., factor IX activity levels) and genetic testing for mutations, are not available in the listed features."
3B11.Z,3B11,"(Hereditary factor IX deficiency, unspecified)",Not Possible,"Key signals for screening hereditary factor IX deficiency, such as specific coagulation factor assays (e.g., factor IX activity), are missing. The available features do not include relevant hematological parameters or genetic testing necessary for effective screening."
3B12,3B12,Von Willebrand disease,Not Possible,"Key features for screening Von Willebrand disease, such as von Willebrand factor levels and specific platelet function tests, are not available in the listed NHANES features."
3B13,3B13,Haemophilia C,Not Possible,"Key signals for screening Haemophilia C, such as specific coagulation factor assays (e.g., factor XI levels), are missing. The available features do not include relevant hematological parameters or genetic markers necessary for effective screening."
3B14.0,3B14,Hereditary deficiency of factor I,Not Possible,"Key signals for screening hereditary deficiency of factor I, such as specific coagulation factor assays (e.g., factor I levels) and genetic testing, are not available in the listed features."
3B14.1,3B14,Hereditary factor X deficiency,Not Possible,"Key signals for screening hereditary factor X deficiency, such as specific coagulation factor assays (e.g., factor X activity), are missing. The available features do not include relevant hematological parameters or genetic markers necessary for effective screening."
3B14.2,3B14,Combined deficiency of vitamin K-dependent clotting factors,Not Possible,"Key signals for screening combined deficiency of vitamin K-dependent clotting factors, such as prothrombin time (PT) and specific vitamin K levels, are missing. The available features do not include coagulation parameters necessary for assessing this condition."
3B14.Z,3B14,"(Other inherited coagulation factor deficiency with bleeding tendency, unspecified)",Not Possible,"Essential signals for screening inherited coagulation factor deficiencies, such as specific factor assays (e.g., factor VIII, factor IX levels) and genetic testing, are missing. The available features do not provide the necessary information to assess bleeding tendencies related to specific factor deficiencies."
3B15,3B15,Inherited coagulation factor deficiency without bleeding tendency,Not Possible,"Key signals for inherited coagulation factor deficiencies, such as specific factor assays (e.g., Factor VIII, Factor IX levels) and genetic testing, are missing. The available features do not provide the necessary information to screen or assess the likelihood of this condition."
3B20,3B20,Disseminated intravascular coagulation,Not Possible,"Key signals for disseminated intravascular coagulation (DIC) such as fibrinogen levels, D-dimer, and specific coagulation factors are missing. These are essential for screening and assessing the likelihood of DIC."
3B21.0,3B21,Haemorrhage due to thrombin inhibitor other than heparin,Not Possible,"Key signals for screening hemorrhage due to thrombin inhibitors, such as specific coagulation parameters (e.g., PT, aPTT, anti-Xa levels) and clinical history of anticoagulant use, are missing."
3B21.1,3B21,Haemorrhage due to factor Xa inhibitor,Not Possible,"Key signals for screening hemorrhage due to factor Xa inhibitors, such as specific coagulation tests (e.g., anti-Xa levels, PT/INR, aPTT), are missing. The available features do not provide sufficient information to assess bleeding risk or anticoagulation status."
3B21.Y,3B21,Haemorrhagic disorder due to other specified circulating anticoagulants,Not Possible,"Key signals such as specific coagulation factor levels, circulating anticoagulants, or specific tests for bleeding disorders are missing. The available features do not provide sufficient information to assess the likelihood of hemorrhagic disorders due to circulating anticoagulants."
3B21.Z,3B21,Haemorrhagic disorder due to unspecified circulating anticoagulants,Not Possible,"Key signals for screening hemorrhagic disorders due to circulating anticoagulants, such as specific coagulation tests (e.g., PT, aPTT, specific inhibitor assays), are missing. The available features do not provide sufficient information on coagulation status or the presence of anticoagulants."
3B22,3B22,Acquired haemophilia,Not Possible,"Acquired hemophilia requires specific tests for factor inhibitors (e.g., aPTT, specific factor assays) and possibly genetic testing, which are not included in the available features. The listed features do not provide the necessary coagulation parameters or specific markers to assess the likelihood of acquired hemophilia."
3B2Y,3B2Y,Other specified haemorrhagic diseases due to acquired coagulation factor defects,Not Possible,"Key signals for screening acquired coagulation factor defects, such as specific coagulation factor levels (e.g., Factor VIII, IX) and functional assays (e.g., PT, aPTT), are missing from the available features."
3B50.0,3B50,Congenital alpha-2 antiplasmin deficiency,Not Possible,"Key signals for screening congenital alpha-2 antiplasmin deficiency, such as specific functional assays for antiplasmin activity or genetic testing for mutations in the SERPINF2 gene, are not available in the listed features."
3B50.1,3B50,Congenital plasminogen activator inhibitor type 1 deficiency,Not Possible,"Key signals for screening congenital plasminogen activator inhibitor type 1 deficiency, such as specific genetic testing or functional assays for plasminogen activator inhibitor levels, are not available in the listed features."
3B50.Y,3B50,Other specified inherited fibrinolytic defects,Not Possible,"Key signals for inherited fibrinolytic defects, such as specific fibrinogen levels, plasminogen activity, or genetic markers, are not included in the available features."
3B50.Z,3B50,"(Inherited fibrinolytic defects, unspecified)",Not Possible,"Key signals for inherited fibrinolytic defects, such as specific fibrinogen levels, plasminogen activity, or D-dimer levels, are not included in the available features."
3B51,3B51,Acquired fibrinolytic defects,Not Possible,"Key signals for acquired fibrinolytic defects, such as specific fibrinogen levels, D-dimer, or other markers of fibrinolysis, are not included in the available features."
3B60.0,3B60,Hereditary vascular purpura,Not Possible,"Key signals for hereditary vascular purpura, such as specific genetic markers or tests for von Willebrand factor levels and function, are not included in the available features."
3B60.1,3B60,Acquired vascular purpura,Not Possible,"Key signals for acquired vascular purpura, such as specific coagulation factors, platelet function tests, or vascular imaging, are missing. The available features do not provide sufficient information to assess the likelihood of this condition."
3B61.0,3B61,Hereditary thrombophilia,Not Possible,"Key signals for hereditary thrombophilia, such as genetic testing for factor mutations (e.g., Factor V Leiden, prothrombin gene mutation) and specific coagulation studies (e.g., protein C, protein S, antithrombin levels), are not available in the listed features."
3B61.00,3B61,Hyperhomocysteinaemia,Not Possible,"Key signals for hyperhomocysteinaemia, such as homocysteine levels, are not included in the available features. Without this critical analyte, screening or likelihood assessment is not feasible."
3B61.0Y,3B61,Other specified hereditary thrombophilia,Not Possible,"Key signals for hereditary thrombophilia, such as genetic markers (e.g., Factor V Leiden, Prothrombin gene mutation) and specific coagulation tests (e.g., protein C, protein S, antithrombin levels), are not available in the listed features."
3B61.0Z,3B61,"(Hereditary thrombophilia, unspecified)",Not Possible,"Key signals for hereditary thrombophilia, such as genetic markers (e.g., Factor V Leiden, Prothrombin gene mutation) and specific coagulation tests (e.g., protein C, protein S, antithrombin levels), are not available in the listed features."
3B61.1,3B61,Acquired thrombophilia,Not Possible,"Key signals for acquired thrombophilia, such as specific coagulation factor levels (e.g., antiphospholipid antibodies, protein C, protein S, and antithrombin levels), are missing. The available features do not provide sufficient information to assess thrombotic risk or diagnose acquired thrombophilia."
3B61.Y,3B61,Other specified thrombophilia,Not Possible,"Key signals for thrombophilia screening, such as genetic markers (e.g., Factor V Leiden, prothrombin mutation) and specific coagulation tests (e.g., antiphospholipid antibodies, protein C/S levels), are missing from the available features."
3B61.Z,3B61,"(Thrombophilia, unspecified)",Not Possible,"Key signals for thrombophilia screening, such as genetic markers (e.g., Factor V Leiden, Prothrombin mutation) and specific coagulation tests (e.g., antiphospholipid antibodies, protein C/S levels), are missing from the available features."
3B62.0,3B62,Inherited qualitative platelet defects,Possible,"The available features include platelet count (LBXPLTSI) and mean platelet volume (LBXMPSI), which are critical for assessing platelet function and can help identify qualitative defects. However, additional specific tests for platelet function (e.g., aggregometry) are not listed, but the existing features allow for a preliminary screening approach."
3B62.00,3B62,Alpha-granule diseases,Not Possible,"Key signals for alpha-granule diseases, such as specific platelet function tests or genetic markers (e.g., ADAMTS13), are not available in the listed features. The available hematological parameters do not provide sufficient specificity or sensitivity for screening this condition."
3B62.01,3B62,Inherited giant platelet disorder,Possible,"The available features include platelet count (LBXPLTSI) and mean platelet volume (LBXMPSI), which are critical for screening inherited giant platelet disorders. These features can help identify abnormalities in platelet size and number, which are indicative of such conditions. Other hematological parameters like white blood cell count and red blood cell indices may also provide supportive information, enhancing the likelihood assessment."
3B62.0Y,3B62,Other specified inherited qualitative platelet defects,Possible,"The available features include platelet count (LBXPLTSI) and mean platelet volume (LBXMPSI), which are critical for assessing qualitative platelet defects. These features can help identify abnormalities in platelet function and morphology, allowing for a probabilistic model to screen for inherited qualitative platelet defects."
3B62.0Z,3B62,"(Inherited qualitative platelet defects, unspecified)",Possible,"The available features include platelet count (LBXPLTSI) and mean platelet volume (LBXMPSI), which are critical for assessing qualitative platelet defects. These features can help identify abnormalities in platelet function, thus enabling screening for inherited qualitative platelet defects."
3B62.1,3B62,Bleeding diathesis due to thromboxane synthesis deficiency,Not Possible,"Key signals for screening bleeding diathesis due to thromboxane synthesis deficiency, such as platelet function tests (e.g., platelet aggregation studies) and thromboxane levels, are not available in the listed features."
3B62.2,3B62,Isolated thrombocytopenia,Possible,"The available features include platelet count (LBXPLTSI) and mean platelet volume (LBXMPSI), which are critical for assessing thrombocytopenia. Additionally, the complete blood count parameters (e.g., white blood cell count, red blood cell count) can help rule out other hematological conditions, thus enabling a meaningful screening for isolated thrombocytopenia."
3B62.3,3B62,Dense granule disease,Not Possible,"Dense granule disease is a type of platelet storage pool disorder, which typically requires specific tests for platelet function and granule content (e.g., platelet aggregation studies, electron microscopy). The available NHANES features do not include any measures of platelet function or granule content, making screening for this condition not feasible."
3B62.4,3B62,Alpha-delta dense granule deficiency,Not Possible,"Key signals for alpha-delta dense granule deficiency, such as platelet function tests and specific granule content analysis, are missing. The available features do not include any direct measures of platelet granule content or function, which are essential for screening this condition."
3B62.5,3B62,Haemophagocytic syndrome associated with infection,Possible,"The available features include key hematological parameters such as white blood cell count (LBXWBCSI), lymphocyte percent (LBXLYPCT), and monocyte percent (LBXMOPCT), which are critical for identifying hemophagocytic syndrome. These features can help assess the likelihood of the syndrome associated with infection by indicating immune activation and cytopenias, which are characteristic of the condition."
3B62.Y,3B62,Other specified qualitative platelet defects,Possible,"The available features include platelet count (LBXPLTSI) and mean platelet volume (LBXMPSI), which are essential for assessing qualitative platelet defects. These features can help identify abnormalities in platelet function and morphology, allowing for a meaningful screening approach."
3B62.Z,3B62,"(Qualitative platelet defects, unspecified)",Possible,"The available features include platelet count (LBXPLTSI) and mean platelet volume (LBXMPSI), which are essential for screening qualitative platelet defects. These features can help identify abnormalities in platelet function and morphology, allowing for a probabilistic model to assess the likelihood of qualitative platelet defects."
3B63.0,3B63,Congenital thrombocytosis,Possible,"The available features include platelet count (LBXPLTSI) and mean platelet volume (LBXMPSI), which are critical for screening congenital thrombocytosis. These features can help identify elevated platelet levels, a key indicator of the condition. Other hematological parameters, such as white blood cell count (LBXWBCSI) and red blood cell indices, can provide additional context but are not essential for initial screening."
3B63.1,3B63,Acquired thrombocytosis,Possible,"The available features include platelet count (LBXPLTSI) and mean platelet volume (LBXMPSI), which are critical for assessing thrombocytosis. Additionally, white blood cell count (LBXWBCSI) and other hematological parameters can help differentiate causes of acquired thrombocytosis, allowing for a meaningful screening approach."
3B63.10,3B63,Secondary thrombocytosis,Possible,"The available features include platelet count (LBXPLTSI) and mean platelet volume (LBXMPSI), which are critical for assessing thrombocytosis. Additionally, white blood cell count (LBXWBCSI) can help identify underlying causes of secondary thrombocytosis, such as inflammation or infection. Age (RIDAGEYR) and gender (RIAGENDR) can also provide demographic context that may influence disease prevalence."
3B63.1Y,3B63,Other specified acquired thrombocytosis,Possible,"The available features include platelet count (LBXPLTSI) and mean platelet volume (LBXMPSI), which are critical for assessing thrombocytosis. Additionally, white blood cell count (LBXWBCSI) and other hematological parameters can help differentiate causes of thrombocytosis, thus enabling a probabilistic model for screening."
3B63.1Z,3B63,"(Acquired thrombocytosis, unspecified)",Possible,"The available features include platelet count (LBXPLTSI) and mean platelet volume (LBXMPSI), which are critical for assessing thrombocytosis. Additionally, white blood cell count (LBXWBCSI) and other hematological parameters can help differentiate causes of thrombocytosis, thus enabling a meaningful screening approach."
3B63.Y,3B63,Other specified thrombocytosis,Possible,"The available features include platelet count (LBXPLTSI) and mean platelet volume (LBXMPSI), which are critical for assessing thrombocytosis. Additionally, white blood cell count (LBXWBCSI) and other hematological parameters can help differentiate between types of thrombocytosis and assess underlying causes."
3B63.Z,3B63,"(Thrombocytosis, unspecified)",Possible,"The available features include platelet count (LBXPLTSI) and mean platelet volume (LBXMPSI), which are critical for assessing thrombocytosis. Additionally, white blood cell count (LBXWBCSI) can help differentiate between reactive and primary causes of thrombocytosis, thus enabling a meaningful screening approach."
3B64.0,3B64,Congenital thrombocytopenia,Possible,"The available features include platelet count (LBXPLTSI) and mean platelet volume (LBXMPSI), which are critical for assessing thrombocytopenia. These features can help identify low platelet levels indicative of congenital thrombocytopenia, allowing for a meaningful screening approach."
3B64.00,3B64,Congenital non-inherited thrombocytopenia,Possible,"The available features include platelet count (LBXPLTSI) and mean platelet volume (LBXMPSI), which are critical for assessing thrombocytopenia. These features can help identify low platelet levels indicative of congenital non-inherited thrombocytopenia, allowing for a meaningful screening approach."
3B64.01,3B64,Hereditary thrombocytopenia,Possible,"The available features include platelet count (LBXPLTSI) and mean platelet volume (LBXMPSI), which are critical for assessing thrombocytopenia. These features can help identify individuals with low platelet counts, a key indicator of hereditary thrombocytopenia. Other hematological parameters such as white blood cell count and red blood cell indices may also provide supportive information."
3B64.0Z,3B64,"(Congenital thrombocytopenia, unspecified)",Possible,"The available features include platelet count (LBXPLTSI) and mean platelet volume (LBXMPSI), which are critical for assessing thrombocytopenia. These features can help identify low platelet levels indicative of congenital thrombocytopenia, allowing for a meaningful screening approach."
3B64.1,3B64,Acquired thrombocytopenia,Possible,"The available features include platelet count (LBXPLTSI) and mean platelet volume (LBXMPSI), which are critical for assessing thrombocytopenia. Additionally, white blood cell count (LBXWBCSI) and hemoglobin (LBXHGB) can help evaluate underlying causes of acquired thrombocytopenia."
3B64.10,3B64,Immune thrombocytopenic purpura,Possible,"The available features include platelet count (LBXPLTSI) and mean platelet volume (LBXMPSI), which are critical for screening immune thrombocytopenic purpura (ITP). Additionally, the complete blood count parameters (e.g., white blood cell count, hemoglobin) can help rule out other causes of thrombocytopenia."
3B64.11,3B64,Secondary thrombocytopenic purpura,Possible,"The available features include platelet count (LBXPLTSI) and mean platelet volume (LBXMPSI), which are critical for assessing thrombocytopenia. Additionally, white blood cell count (LBXWBCSI) and other hematological parameters can help evaluate underlying causes of secondary thrombocytopenic purpura."
3B64.12,3B64,Drug-induced thrombocytopenic purpura,Possible,"The available features include platelet count (LBXPLTSI) and white blood cell count (LBXWBCSI), which are critical for assessing thrombocytopenia and potential drug-induced causes. Additionally, demographic features like age (RIDAGEYR) and gender (RIAGENDR) can help stratify risk. However, the absence of specific drug exposure data limits the ability to definitively diagnose drug-induced thrombocytopenic purpura, but screening for thrombocytopenia is feasible."
3B64.13,3B64,Alloimmune thrombocytopenia,Not Possible,"Alloimmune thrombocytopenia requires specific markers such as platelet antibodies or HLA typing for diagnosis, which are not included in the available features. The listed features do not provide sufficient information to assess the likelihood of this condition."
3B64.14,3B64,Thrombotic thrombocytopenic purpura,Not Possible,"Key signals for thrombotic thrombocytopenic purpura (TTP) such as ADAMTS13 activity, inhibitor levels, and specific clinical features (e.g., schistocytes on blood smear) are missing. While platelet count and hemolysis indicators (like LDH) are available, they are insufficient for a reliable screening or likelihood assessment for TTP."
3B64.1Y,3B64,Other specified acquired thrombocytopenia,Possible,"The available features include platelet count (LBXPLTSI) and mean platelet volume (LBXMPSI), which are critical for assessing thrombocytopenia. Additionally, white blood cell count (LBXWBCSI) and other hematological parameters can help differentiate causes of thrombocytopenia, thus enabling a probabilistic model for screening."
3B64.Z,3B64,"(Thrombocytopenia, unspecified)",Possible,"The available features include platelet count (LBXPLTSI) and mean platelet volume (LBXMPSI), which are critical for screening thrombocytopenia. Additionally, the complete blood count parameters (WBC, RBC, hemoglobin, hematocrit) provide supportive information for evaluating hematological status, allowing for a probabilistic model to assess thrombocytopenia likelihood."
3B65,3B65,"(Thrombotic microangiopathy, not elsewhere classified)",Not Possible,"Key signals for thrombotic microangiopathy, such as ADAMTS13 activity, platelet function tests, and specific markers of hemolysis (e.g., haptoglobin, schistocytes), are missing. The available features do not provide sufficient information to screen or assess likelihood effectively."
3B6Y,3B6Y,"(Other specified coagulation defects, purpura or other haemorrhagic or related conditions)",Not Possible,"Key signals for screening coagulation defects, such as specific coagulation factor levels (e.g., factor VIII, factor IX), platelet function tests, or genetic markers, are missing. The available features do not provide sufficient information to assess bleeding risk or coagulation status."
3B6Z,3B6Z,"(Coagulation defects, purpura or other haemorrhagic or related conditions, unspecified)",Possible,"The available features include key hematological parameters such as platelet count (LBXPLTSI), white blood cell count (LBXWBCSI), hemoglobin (LBXHGB), and red blood cell count (LBXRBCSI), which can help identify coagulation defects and related hemorrhagic conditions. However, the absence of specific coagulation factors or tests (e.g., PT, aPTT, or specific factor assays) limits the precision of the screening. Nonetheless, the existing features can still provide a reasonable basis for initial screening and risk assessment."
3B80.0,3B80,Splenomegaly in storage diseases,Not Possible,"Key signals for diagnosing splenomegaly in storage diseases, such as imaging studies (e.g., ultrasound, CT scan) and specific biochemical markers (e.g., enzyme levels related to specific storage diseases), are not available in the listed features."
3B81.0,3B81,Tumour-like conditions of spleen,Not Possible,"Key signals such as imaging studies (e.g., ultrasound, CT scan) or specific biomarkers related to splenic pathology are missing, which are essential for screening tumor-like conditions of the spleen."
3B81.1,3B81,Postsurgical asplenia,Not Possible,"Key signals for screening postsurgical asplenia, such as immunological markers (e.g., antibody levels) and clinical history of splenectomy, are missing. The available features do not provide sufficient information to assess the risk of infections or other complications associated with asplenia."
3B81.2,3B81,Atrophy of spleen,Not Possible,"Atrophy of the spleen is often associated with underlying hematological conditions or infections, which may be indicated by imaging studies or specific laboratory tests (e.g., spleen size, specific antibody tests). The available features do not include any imaging or specific markers that would allow for effective screening or likelihood assessment of splenic atrophy."
3B81.3,3B81,Nontraumatic laceration or rupture of spleen,Not Possible,"Key signals such as imaging studies (e.g., ultrasound or CT scan) to identify splenic laceration or rupture are missing. Additionally, clinical features like trauma history or specific physical examination findings are not available, which are essential for screening this condition."
3B81.4,3B81,Splenosis,Not Possible,"Key signals for splenosis, such as imaging studies (e.g., ultrasound, CT scan) to visualize ectopic splenic tissue, are not available. Additionally, specific laboratory tests that could indicate splenic function or dysfunction (e.g., splenic enzyme levels) are also missing."
3B81.5,3B81,Splenic cyst or pseudocyst,Not Possible,"Key imaging features (e.g., ultrasound or CT scans) necessary for diagnosing splenic cysts or pseudocysts are not available in the listed NHANES features."
3B81.50,3B81,Pseudocyst of spleen,Not Possible,"Key imaging features (e.g., ultrasound or CT scans) and specific laboratory tests (e.g., serum amylase or lipase) that are critical for diagnosing splenic pseudocysts are not available in the listed features."
3B81.51,3B81,Epithelial cyst of spleen,Not Possible,"Epithelial cysts of the spleen typically require imaging studies (e.g., ultrasound, CT scan) for diagnosis, which are not included in the available features. The listed hematological parameters do not provide sufficient diagnostic information for screening or likelihood assessment of this condition."
3B81.5Y,3B81,Other specified splenic cyst,Not Possible,Key imaging features or specific markers for splenic cysts are missing; available hematological features do not provide sufficient diagnostic information for screening or likelihood assessment of splenic cysts.
3B81.5Z,3B81,"(Splenic cyst, unspecified)",Not Possible,"Key imaging features (e.g., ultrasound or CT scans) necessary for diagnosing splenic cysts are not available, making screening for this condition infeasible."
3B81.6,3B81,Infarction of spleen,Not Possible,"Key signals for screening splenic infarction, such as imaging studies (e.g., ultrasound, CT scan) or specific markers of splenic function and blood flow, are missing. The available hematological features do not provide sufficient information to assess the likelihood of splenic infarction."
3B81.7,3B81,Infection of spleen,Possible,"The available features include key hematological parameters such as white blood cell count (LBXWBCSI), lymphocyte percent (LBXLYPCT), and neutrophil percent (LBXNEPCT), which can indicate infection or inflammation, including splenic infections. These features can help build a probabilistic model to assess the likelihood of splenic infection."
3B81.70,3B81,Acute septic splenitis,Possible,"The available features include key hematological parameters such as white blood cell count (LBXWBCSI), neutrophil percentage (LBXNEPCT), and monocyte percentage (LBXMOPCT), which are critical for identifying acute infections like septic splenitis. These features can help assess the likelihood of infection and inflammation, thus supporting screening efforts."
3B81.71,3B81,Abscess of spleen,Possible,"The available features include key hematological parameters such as white blood cell count (LBXWBCSI), which can indicate infection or inflammation, and other blood cell differentials (e.g., neutrophils, lymphocytes) that are relevant in assessing splenic abscesses. These features can help build a probabilistic model for screening, although imaging or direct assessment of the spleen is not available."
3B81.7Y,3B81,Other specified infection of spleen,Possible,"The available features include key hematological parameters such as white blood cell count (LBXWBCSI), lymphocyte percent (LBXLYPCT), and monocyte percent (LBXMOPCT), which can indicate infection or inflammation. These features can help in screening for infections of the spleen, as changes in these parameters are often associated with infectious processes. However, imaging or specific microbiological tests would enhance diagnostic accuracy, but are not strictly necessary for initial screening."
3B81.7Z,3B81,"(Infection of spleen, unspecified)",Possible,"The available features include key hematological parameters such as white blood cell count (LBXWBCSI), lymphocyte percent (LBXLYPCT), and neutrophil percent (LBXNEPCT), which can indicate infection or inflammation, including splenic infections. These features can help build a probabilistic model to assess the likelihood of an infection of the spleen."
3B81.8,3B81,Torsion of spleen,Not Possible,"Torsion of the spleen typically requires imaging studies (e.g., ultrasound, CT scan) for diagnosis, which are not included in the available features. The listed hematological parameters do not provide sufficient diagnostic signals for screening or likelihood assessment of splenic torsion."
3B81.9,3B81,Fibrosis of spleen,Not Possible,"Key signals for screening fibrosis of the spleen, such as imaging studies (ultrasound, CT scan) or specific biomarkers (e.g., spleen size, portal hypertension indicators), are missing. The available hematological features do not provide sufficient specificity or sensitivity for this condition."
3B81.A,3B81,Perisplenitis,Not Possible,"Perisplenitis typically requires imaging studies (e.g., ultrasound or CT scan) to assess splenic inflammation or enlargement, which are not included in the available features. Additionally, specific clinical history and physical examination findings are crucial for diagnosis, which cannot be captured by the listed laboratory measurements alone."
3B81.B,3B81,Hypersplenism,Possible,"Key hematological features such as white blood cell count (LBXWBCSI), red blood cell count (LBXRBCSI), hemoglobin (LBXHGB), hematocrit (LBXHCT), and platelet count (LBXPLTSI) are available, which can help assess splenic function and potential hypersplenism. However, the absence of direct measures of splenic size or function (e.g., imaging or specific biomarkers) limits the precision of the assessment."
3B81.C,3B81,Chronic congestive splenomegaly,Not Possible,"Chronic congestive splenomegaly typically requires imaging studies (e.g., ultrasound, CT) or specific laboratory tests (e.g., liver function tests, portal hypertension markers) to assess splenic size and function, which are not available in the listed features."
3B81.Y,3B81,Other specified acquired disorders of spleen,Possible,"The available features include key hematological parameters such as white blood cell count (LBXWBCSI), lymphocyte percent (LBXLYPCT), and lactate dehydrogenase (LBXSLDSI), which can indicate splenic dysfunction or disorders. These features can help in screening for acquired disorders of the spleen by assessing blood cell counts and potential hemolysis, thus enriching disease prevalence assessment."
3B81.Z,3B81,"(Acquired disorders of spleen, unspecified)",Possible,"The available features include key hematological parameters such as white blood cell count (LBXWBCSI), lymphocyte percent (LBXLYPCT), and lactate dehydrogenase (LBXSLDSI), which can indicate splenic dysfunction or disorders. These features can help in screening for acquired disorders of the spleen by assessing blood cell counts and potential hemolysis, thus enriching disease prevalence assessment."
3B8Z,3B8Z,"(Diseases of spleen, unspecified)",Possible,"The available features include complete blood count parameters (WBC, lymphocytes, monocytes, neutrophils, eosinophils, basophils, hemoglobin, hematocrit, and platelet counts) which can indicate splenic function or dysfunction. These hematological parameters can help identify conditions related to splenic diseases, such as hypersplenism or splenic sequestration, thus allowing for a meaningful screening approach."
3C0Y,3C0Y,Other specified diseases of the blood or blood-forming organs,Possible,"The available features include key hematological parameters such as white blood cell count, red blood cell count, hemoglobin, hematocrit, and various white blood cell differentials (lymphocytes, monocytes, neutrophils, eosinophils, basophils). These features can help identify abnormalities in blood cell production and function, which are essential for screening various blood disorders."
3C0Z,3C0Z,"(Diseases of the blood or blood-forming organs, unspecified)",Possible,"The available features include key hematological parameters such as white blood cell count, red blood cell count, hemoglobin, hematocrit, and platelet count, which are essential for screening various blood disorders. These features can help identify abnormalities indicative of diseases of the blood or blood-forming organs."
